See more : Carrier Global Corporation (4PN.DE) Income Statement Analysis – Financial Results
Complete financial analysis of The India Fund, Inc. (IFN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of The India Fund, Inc., a leading company in the Asset Management industry within the Financial Services sector.
You may be interested
- Seiryo Electric Corporation (4341.T) Income Statement Analysis – Financial Results
- Anhui Kouzi Distillery Co., Ltd. (603589.SS) Income Statement Analysis – Financial Results
- The Gummy Project Inc. (GUMYF) Income Statement Analysis – Financial Results
- Hilton Metal Forging Limited (HILTON.NS) Income Statement Analysis – Financial Results
- Kyoshin Co., Ltd. (4735.T) Income Statement Analysis – Financial Results
The India Fund, Inc. (IFN)
Industry: Asset Management
Sector: Financial Services
Website: https://www.aberdeenifn.com/aam.nsf/usClosedIfn/home
About The India Fund, Inc.
The India Fund, Inc. is a close ended equity mutual fund launched and managed by Aberdeen Standard Investments (Asia) Limited. The fund invests in public equity markets of India. It seeks to invest in stocks of small-cap, mid-cap, and large-cap companies. The fund employs a quantitative and fundamental analysis with a bottom-up stock picking and asset allocation approach to create its portfolio. It benchmarks the performance of its portfolio against the IFC Investable India Index. The India Fund, Inc. was formed on December 27, 1993 and is domiciled in the Singapore.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.45M | -104.42M | 101.26M | 64.71M | 30.89M | -33.60M | 239.32M | 10.20M | 11.86M | 14.77M | 13.87M | 15.50M | 16.91M | 20.65M | 12.72M | 18.17M | 21.24M | 15.56M | 15.60M | 10.69M | 9.94M | 8.71M | 9.00M | 5.69M |
| Cost of Revenue | 56.43M | 6.95M | 7.88M | 6.63M | 7.59M | 9.10M | 9.75M | 8.70M | 9.65M | 9.43M | 9.68M | 10.26M | 13.20M | 16.08M | 10.77M | 15.98M | 21.32M | 15.38M | 11.89M | 7.20M | 5.61M | 5.10M | 5.43M | 8.76M |
| Gross Profit | -50.98M | -111.36M | 93.39M | 58.08M | 23.30M | -42.70M | 229.57M | 1.51M | 2.22M | 5.34M | 4.19M | 5.24M | 3.71M | 4.57M | 1.95M | 2.19M | -80.00K | 180.00K | 3.71M | 3.49M | 4.33M | 3.61M | 3.57M | -3.07M |
| Gross Profit Ratio | -935.57% | 106.65% | 92.22% | 89.76% | 75.44% | 127.08% | 95.92% | 14.76% | 18.68% | 36.17% | 30.22% | 33.81% | 21.94% | 22.13% | 15.33% | 12.05% | -0.38% | 1.16% | 23.78% | 32.65% | 43.56% | 41.45% | 39.67% | -53.95% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.89M | 1.81M | 1.88M | 1.78M | 1.79M | 2.12M | 1.97M | 10.07M | 11.26M | 10.04M | 10.03M | 2.68M | 5.03M | 5.39M | 3.28M | 4.93M | 6.18M | 5.15M | 2.54M | 1.64M | 1.39M | 1.18M | 1.27M | 1.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 122.66K | 129.28K | 130.43K | 126.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.89M | 1.81M | 1.88M | 1.78M | 1.79M | 2.12M | 1.97M | 10.19M | 11.39M | 10.17M | 10.16M | 2.68M | 5.03M | 5.39M | 3.28M | 4.93M | 6.18M | 5.15M | 2.54M | 1.64M | 1.39M | 1.18M | 1.27M | 1.95M |
| Other Expenses | 0.00 | 62.90K | 24.55K | 25.51K | 25.04K | 24.31K | 23.04K | 209.90K | 337.02K | -1.78M | -1.90M | -2.07M | -490.00K | 60.00K | -960.00K | 50.00K | 30.00K | 60.00K | 50.00K | 50.00K | 50.00K | 60.00K | 30.00K | 50.00K |
| Operating Expenses | 92.41M | 1.88M | 1.91M | 1.81M | 1.82M | 2.14M | 2.00M | 12.83M | 38.17M | 217.91M | 12.75M | 610.00K | 4.54M | 5.45M | 2.32M | 4.98M | 6.21M | 5.21M | 2.59M | 1.69M | 1.44M | 1.24M | 1.30M | 2.00M |
| Cost & Expenses | 92.41M | 1.88M | 1.91M | 1.81M | 1.82M | 2.14M | 2.00M | 12.83M | 38.17M | 217.91M | 12.75M | 10.87M | 17.74M | 21.53M | 13.09M | 20.96M | 27.53M | 20.59M | 14.48M | 8.89M | 7.05M | 6.34M | 6.73M | 10.76M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 230.19M | 0.00 | 177.63M | -561.51M | 313.43M | 664.09M | -1.64B | 1.39B | 587.80M | 364.72M | 138.70M | 277.80M | 18.55M | -133.30M | -232.31M |
| Depreciation & Amortization | 0.00 | 2.26M | 3.11M | 1.03M | -810.66K | 969.87K | 186.28K | 51.81K | -435.99K | -2.49M | -3.67M | 355.26M | -1.12B | 626.86M | 1.33B | -3.29B | 2.77B | 1.18B | 729.44M | 277.40M | 555.61M | 37.10M | -266.60M | -464.61M |
| EBITDA | 97.60M | -103.55M | 0.00 | 0.00 | 29.07M | -33.81M | 0.00 | -2.58M | -26.75M | 230.19M | -2.54M | 359.89M | -1.12B | 625.98M | 1.33B | -3.29B | 2.77B | 1.17B | 730.57M | 279.21M | 558.49M | 39.47M | -264.33M | -469.69M |
| EBITDA Ratio | 1,791.10% | 101.80% | 98.12% | 97.21% | 94.12% | 106.37% | 99.17% | -25.28% | -225.45% | 1,558.12% | -18.33% | 2,321.87% | -6,646.07% | 3,031.38% | 10,438.68% | -18,113.10% | 13,024.11% | 7,522.94% | 4,683.14% | 2,611.88% | 5,618.61% | 453.16% | -2,937.00% | -8,254.66% |
| Operating Income | -143.39M | -106.29M | 99.36M | 62.91M | 29.07M | -35.74M | 237.33M | -51.81K | 435.99K | 2.49M | 3.67M | 4.63M | -830.00K | -880.00K | -370.00K | -2.79M | -6.29M | -5.03M | 1.13M | 1.81M | 2.88M | 2.37M | 2.27M | -5.08M |
| Operating Income Ratio | -2,631.51% | 101.80% | 98.12% | 97.21% | 94.12% | 106.37% | 99.17% | -0.51% | 3.68% | 16.88% | 26.45% | 29.87% | -4.91% | -4.26% | -2.91% | -15.35% | -29.61% | -32.33% | 7.24% | 16.93% | 28.97% | 27.21% | 25.22% | -89.28% |
| Total Other Income/Expenses | 241.25M | 0.00 | -177.50K | -52.51K | 0.00 | 0.00 | 515.34K | -2.58M | -26.75M | 230.19M | -2.54M | 177.63M | -561.51M | 313.43M | 664.08M | -1.64B | 1.39B | 587.80M | 364.72M | 138.70M | 277.81M | 18.55M | -133.30M | -232.30M |
| Income Before Tax | 97.86M | -106.29M | 99.36M | 62.91M | 29.07M | -35.74M | 237.33M | -2.63M | -26.31M | 232.68M | 1.13M | 182.26M | -562.34M | 312.55M | 663.71M | -1.65B | 1.38B | 582.77M | 365.85M | 140.51M | 280.69M | 20.92M | -131.03M | -237.38M |
| Income Before Tax Ratio | 1,795.94% | 101.80% | 98.12% | 97.21% | 94.12% | 106.37% | 99.17% | -25.79% | -221.77% | 1,575.00% | 8.12% | 1,175.87% | -3,325.49% | 1,513.56% | 5,217.85% | -9,064.23% | 6,497.27% | 3,745.31% | 2,345.19% | 1,314.41% | 2,823.84% | 240.18% | -1,455.89% | -4,171.88% |
| Income Tax Expense | 0.00 | -2.75M | -3.29M | -1.09M | 458.63K | -1.93M | 329.06K | -2.58M | -26.75M | 59.58K | 46.16K | 0.00 | -4.96M | 0.00 | 0.00 | 0.00 | 0.00 | -20.55M | 25.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 97.86M | -106.29M | 99.36M | 62.91M | 29.07M | -35.74M | 237.33M | -2.63M | -26.31M | 232.62M | 1.08M | 182.26M | -557.38M | 312.55M | 663.71M | -1.65B | 1.38B | 603.32M | 340.34M | 140.51M | 280.69M | 20.92M | -131.03M | -237.38M |
| Net Income Ratio | 1,795.94% | 101.80% | 98.12% | 97.21% | 94.12% | 106.37% | 99.17% | -25.79% | -221.77% | 1,574.59% | 7.79% | 1,175.87% | -3,296.16% | 1,513.56% | 5,217.85% | -9,064.23% | 6,497.27% | 3,877.38% | 2,181.67% | 1,314.41% | 2,823.84% | 240.18% | -1,455.89% | -4,171.88% |
| EPS | 3.20 | -3.87 | 3.69 | 2.34 | 1.08 | -1.33 | 8.36 | -0.09 | -0.90 | 7.86 | 0.03 | 4.94 | -13.65 | 7.06 | 13.53 | -42.66 | 32.46 | 13.45 | 10.70 | 6.21 | 11.97 | 0.76 | -4.27 | -7.61 |
| EPS Diluted | 3.20 | -3.87 | 3.69 | 2.34 | 1.08 | -1.29 | 8.36 | -0.09 | -0.90 | 7.86 | 0.03 | 4.94 | -13.65 | 7.06 | 13.53 | -42.66 | 32.46 | 13.45 | 10.70 | 6.21 | 11.97 | 0.76 | -4.27 | -7.61 |
| Weighted Avg Shares Out | 30.57M | 27.47M | 26.90M | 26.90M | 26.90M | 26.93M | 27.98M | 28.46M | 29.25M | 29.61M | 34.94M | 36.86M | 40.84M | 44.28M | 49.07M | 38.61M | 42.52M | 44.87M | 31.81M | 22.64M | 23.44M | 27.57M | 30.72M | 31.20M |
| Weighted Avg Shares Out (Dil) | 30.57M | 27.47M | 26.90M | 26.90M | 26.90M | 27.71M | 28.39M | 28.46M | 29.25M | 29.61M | 34.94M | 36.86M | 40.84M | 44.28M | 49.07M | 38.61M | 42.52M | 44.87M | 31.81M | 22.64M | 23.44M | 27.57M | 30.72M | 31.20M |
5 Best CEFs This Month For Nearly 9% Yield (July 2024)
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper draw-downs than the broader market....
The India Fund Inc. Announces Payment of Distribution
PHILADELPHIA, PA / ACCESSWIRE / July 5, 2024 / The India Fund, Inc. ("IFN") (the "Fund"), today announced that the Fund paid the distribution noted in the table below on July 5, 2024, on a per share basis to all...
5 Best CEFs This Month For A 9% Yield (June 2024)
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper draw-downs than the broader market....
IFN: Rights Offering Results
IFN completes its rights offering. A sell and rebuy strategy would have worked once again. IFN is a decent choice for those looking for Indian stock market exposure.
The India Fund, Inc. Announces Distribution Payment Details
PHILADELPHIA, PA / ACCESSWIRE / May 20, 2024 / The India Fund, Inc. (NYSE:IFN), announced today that it will pay $0.45 on a per share basis on July 5, 2024 to all shareholders of record as of May 30, 2024...
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10 cycles of SON-1010 with atezolizumab (Tecentriq®) without...
The India Fund, Inc. (NYSE:IFN) Shares Purchased by National Bank of Canada FI
National Bank of Canada FI boosted its holdings in shares of The India Fund, Inc. (NYSE:IFN – Free Report) by 233.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm...
5 Best CEFs This Month For A 10% Yield (May 2024)
For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper draw-downs than the broader market....
abrdn U.S. Closed-End Funds Announce Results of Annual Meeting of Shareholders
PHILADELPHIA, PA / ACCESSWIRE / May 16, 2024 / The following abrdn U.S. Closed-End Funds (NYSE:ACP),(NYSE:AGD),(NYSE:AOD),(NYSE:ASGI),(NYSE:AWP),(NYSE:IFN),(NYSE:JEQ) and (NYSE American:FAX),(NYSE American:FCO),(NYSE American:IAF) and (NYSE American:AEF) announced they each held their Annual Meeting of Shareholders (the "Meetings") on May 16, 2024. At...
The India Fund, Inc. Announces Final Results of Its Rights Offering
PHILADELPHIA, PA / ACCESSWIRE / May 15, 2024 / The India Fund, Inc. (NYSE:IFN) (the "Fund"), a closed-end fund, announced today the successful completion of its transferable rights ("Rights") offering (the "Offer"). The Offer commenced on April 19, 2024, and...
Source: https://incomestatements.info
Category: Stock Reports